CD4 and pneumocystosis: PJP incidence remains low likely related to widespread use of prophylaxis for a reported 3–6 months starting after neutrophil recovery and/or low rates of sustained CD4 lymphopenia among BCMA CAR-T, though further data is needed (22, 49).